Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05551754
Other study ID # 852002
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date October 20, 2022
Est. completion date July 2025

Study information

Verified date January 2024
Source University of Pennsylvania
Contact Timothy S Pond, MPH
Phone 2157461959
Email timpond@pennmedicine.upenn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single blinded, randomized trial to evaluate the immediate subjective and objective effects of alcohol after a dose ketone supplement compared to a placebo in 10 health volunteers. Subjects will complete 2 lab visits where they consume a dose of alcohol (based on weight), to bring their breath alcohol concentration to about 0.050%. Participants will randomly receive ketone supplement at one lab and the placebo at the next lab.


Description:

The purpose of the study is to evaluate the immediate subjective and objective effects of alcohol after consuming a ketone supplement beverage, compared to a placebo beverage (an inactive substance). Participants will not know which lab they receive the ketone drink, however they will be asked to drink an alcohol beverage (based on weight), to bring breath alcohol concentration (BrAC) to about 0.050% at each lab visit. The goal of the study is to see how measure subjective effects of alcohol, once after drinking the ketone supplement and once after drinking a placebo beverage. The study will use questionnaires, blood, and breath alcohol tests to see how subjects body and brain experience alcohol. The study is also interested in if the ketone supplement makes people want to drink alcohol more or less. Consent and Screening Session (approximately 3 hrs) The following will occur at the screening session, following signed consent: - First, subjects will be asked to show a legal photo ID and then undergo a breathalyzer test to ensure that they are able to make a well-reasoned decision about whether or not to participate in the study. The BrAC must be at 0.000% to complete this visit. - Demographic information, such as date of birth, age, biological sex, marital status, education, race, and ethnicity will be collected. - Subjects will be asked to provide current information about address and contact information to register them as a patient at the University of Pennsylvania, if they have not been a patient here before. - Approximately 2 tablespoons of blood for standard laboratory tests will be drawn. It is possible that bloodwork will need to be repeated due to unforeseen events (abnormal findings or potential lab errors). - Subject's will be asked to provide a urine sample for routine urinalysis, drug screen, and a pregnancy test in women who are able to become pregnant. - Study personnel will measure vital signs (blood pressure and pulse), weight, and height. Subject's will be asked to complete a questionnaire about current and past medical history and any medications currently taking. - Study personnel will complete a brief psychiatric interview and ask about alcohol and cigarette use over the past 90 days. Staff will confirm eligible within 5 business days after the screening visit, to schedule the rest of the study visits. Lab visits (approximately 5 1/2 hrs) The following will occur on the day of the two lab visits as a participant. - Subject's are asked to not eat or drink anything except water after midnight the day before and on the day of the lab visit. A light meal will be provided on the lab days, after staff takes a BrAC (must be 0.000% to continue), preforms a finger stick for blood glucose level (must be below 140), measures weight, and vital signs. - Subjects will be asked to provide a urine sample to conduct a drug screen, and a pregnancy test (for woman able to become pregnant). - Staff will review the current list medications and vitamins provided at the screening visit and ask if anything has changed? - Subjects will be asked about alcohol and drug use history since the last visit. - Approximately 1 hour after the light meal, subjects will be asked to drink the ketone supplement or placebo beverage. - Approximately 30 minutes after drinking the beverage, subjects will be asked to drink an alcohol beverage based on weight in 15 minutes. Staff will record the BrAC, draw blood and ask subjects to complete questionnaire as listed in the below table. - Staff will ask about any side effects that may occur throughout the lab procedures. - During the lab day between study procedures, subjects may read books, magazines, or watch videos. - After a snack, staff will check the final BrAC and ask again about any side effects. The second visit will be scheduled at least 2 days after the first visit and will follow the same procedures. Subjects may leave with a BrAC below 0.010. Table of assessments on Lab Visits: - Approximate study times • Procedure - 10:30am • BrAC1, vital signs, urine sample - 10:40am • light meal - 11:00am • Review of medications currently taking, and review of alcohol and drug use since last visit - 12:00pm • Ketone supplement or placebo drink - 12:20pm • BrAC 2, and 3 questionnaires - 12:30pm • Finger stick - Alcohol administration - 12:45pm • BrAC 3, and blood draw 1 - 1:00pm • BrAC 4, and 2 questionnaires - 1:15pm • BrAC 5, and blood draw 2 - 1:30pm • BrAC 6, and 2 questionnaires - 2:00pm • BrAC 7, Blood draw 3, and 3 questionnaires - 2:30pm • BrAC 8 - 3:00pm • BrAC 9 - 3:30pm • BrAC 10, blood draw 4, and 3 questionnaires - 3:50pm • Snack - 4:00pm • Final BrAC end of visit. Follow-up Visit (approximately 5 minutes): A follow-up phone call will occur the day after each lab visit and the following will occur: • Staff will ask about any side effects that may have been experienced.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date July 2025
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria: 1. Willingness to provide signed, informed consent and commit to completing the alcohol lab studies. 2. All subjects must report at least one occasion in the prior month of drinking at least 2 drinks on a single day. Exclusion Criteria: 1. Unwilling or unable to refrain from use, within 24 hours of alcohol lab procedures, psychoactive medications or medications that may affect study results. 2. Current DSM-5 diagnosis of a major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders) (identified by clinical examination or the structured interview) that could interfere with study participation or make it hazardous for the subject. 3. Currently taking a medication that could interfere with study participation or make it hazardous for the subject to participate. (e.g., anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified) 4. Positive urine drug screen positive for all substances but marijuana on study visits (may be repeated once and if the result is negative on repeat it is not exclusionary). 5. A baseline breath alcohol concentration of greater than 0.00% on study visit prior to alcohol tolerance test 6. A current, clinically significant physical disease or abnormality on the basis of medical history, or routine laboratory evaluation that can impact brain function, the use of a ketone supplement or the use of alcohol (e.g., epilepsy, diabetes, irritable bowel syndrome, Crohn's disease, liver disease, kidney disease, kidney stones, chronic metabolic acidosis or a cardiomyopathy as determined by history and clinical exam). 7. Currently suffering from or with a history of stroke and/or stroke related spasticity. 8. Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture or inter-cranial bleeding or abnormal MRI. (self-report, medical history). 9. Weight greater than 225lbs (Need to cap amount of alcohol give based on weight to individuals). 10. Judged by the principal investigator or his designee to be an unsuitable candidate for study participation.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Ketone Supplement
Drink a single dose of ketone supplement 25g
Other:
Alcohol Beverage
Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%

Locations

Country Name City State
United States University of Pennsylvania Center for Studies of Addiction Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute effects of breath/blood alcohol levels in response to ketone supplement verse placebo Change in breath/blood alcohol levels (grams per 210 Liters of breath) in response to ketone supplement verse placebo 4 hours
Secondary Acute effects of subjective reports of intoxication and alcohol craving in response to ketone supplement verse placebo after alcohol drinks. Change in subjective effects are measured using the Drug Effects Questionnaire (DEQ): A 5-item scale assessing the extent to which participants (1) feel any DRUG EFFECTS, (2) feel HIGH, (3) LIKE the effects, (4) DISLIKE the effects, and (5) want MORE of the substance using a 100-mm visual analogue scale. 4 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05414344 - A Brief Intervention for Alcohol Users With Interpersonal Trauma N/A
Completed NCT05521906 - Evaluation of PRYSHM for LGBTQIA2S+ Youth N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Withdrawn NCT04659278 - Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use N/A
Not yet recruiting NCT03632408 - Hangover and Residual Zopiclone Effect on Spatial Perception Phase 1
Completed NCT02718508 - An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use N/A
Active, not recruiting NCT02629679 - Sports, Education and Consumption of Substances in Adolescents N/A
Completed NCT02945371 - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life N/A
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Completed NCT01081119 - Brief Voluntary Alcohol and Drug Intervention for Middle School Youth Phase 2
Completed NCT04510116 - Adults In The Making Prevention Trial N/A
Completed NCT00289965 - Substance Use Risk Education (SURE) Project Phase 2
Completed NCT00506753 - Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail N/A
Recruiting NCT05288790 - Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT Phase 2
Recruiting NCT05620849 - Young Adult Education on Alcohol & Health N/A
Recruiting NCT04054466 - Nursing Counseling to the Change of Behavior of Alcohol Consumption in Patients in HAART N/A
Recruiting NCT03588754 - Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking? Phase 2
Recruiting NCT06074341 - TeleHealth Resources for IndiVidualizEd Goals (THRIVE) in Alcohol Recovery Study N/A
Terminated NCT04596267 - Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers Phase 1